Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Active not recruiting 4Withdrawn 2Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Prostatic Neoplasms 9Glioblastoma 9Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Brain Neoplasms 6Glioma 5Breast Neoplasms 5Oligodendroglioma 4Neoplasm Metastasis 4Multiple Myeloma 4Colorectal Neoplasms 4Astrocytoma 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Neoplasms 3Meningioma 3Medulloblastoma 3Gliosarcoma 3Glioma, Subependymal 3Ependymoma 3Central Nervous System Neoplasms 3Carcinoma, Renal Cell 3Sarcoma 2Platinum-Refractory Fallopian Tube Carcinoma 2Pinealoma 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma 2Hematologic Neoplasms 2

Interventions

fludarabine 6Cyclophosphamide 5fludarabine phosphate 4Whole-Body Irradiation 4itacitinib 3angiotensin I (1-7) 3pembrolizumab 2Tacrolimus 2Olanzapine 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2INCB039110 2CTLA-4 Antigen 2Busulfan 2Brentuximab Vedotin 2Bendamustine Hydrochloride 2AP 1903 reagent 2tazemetostat 1tafasitamab 1ruxolitinib 1pomalidomide 1ofatumumab 1merphos 1lopinavir-ritonavir drug combination 1ivosidenib 1ibrutinib 1fedratinib 1enasidenib 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Hematologic Neoplasms × Magnetic Resonance Spectroscopy × Clear all
NCT05600556 2025-05-15

Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT)

Thomas Jefferson University

Phase NA Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT04605614 2022-06-09

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

City of Hope Medical Center

Phase 1 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡